Gain Therapeutics’ (GANX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.68) EPS.

Other equities analysts have also issued reports about the stock. Oppenheimer restated an “outperform” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Wednesday, August 14th. Chardan Capital restated a “buy” rating and issued a $6.00 price objective on shares of Gain Therapeutics in a research note on Friday, August 9th.

Gain Therapeutics Trading Up 0.6 %

NASDAQ:GANX opened at $1.74 on Monday. The company has a market capitalization of $46.14 million, a PE ratio of -1.58 and a beta of 0.33. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $5.33. The stock’s 50 day moving average price is $2.08 and its 200 day moving average price is $1.71. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On Gain Therapeutics

Several large investors have recently modified their holdings of GANX. Geode Capital Management LLC grew its position in Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after acquiring an additional 72,000 shares during the period. Warberg Asset Management LLC acquired a new position in shares of Gain Therapeutics during the second quarter worth about $66,000. Finally, Hohimer Wealth Management LLC purchased a new position in Gain Therapeutics during the second quarter worth about $422,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.